Fibromyalgia
Conditions
Keywords
tDCS, Therapeutic exercise, Referred pain, Central sensitization
Brief summary
The purpose of this study is to assess the effects on pain of transcranial direct current stimulation combined with therapeutic exercise in fibromyalgia patients.
Detailed description
Fibromyalgia is one of the rheumatic diseases with the greatest impact on the quality of life, whose etiology and pathophysiology is not yet fully demonstrated. Perhaps this is why its therapeutic approach is refractory to current treatments. Based on the theory that fibromyalgia is characterized by a sensitization at the level of the central nervous system that leads to an increase in the perception of pain, any therapeutic approach aimed at modulating the central nervous system may be beneficial. Electrical stimulation with transcranial direct current (tDCS) is among these techniques. In the same way, therapeutic exercise has shown to have, like the tDCS, a beneficial effect on pain in different chronic pathologies. The present study aims to investigate the effect on pain of a combination therapy of tDCS and therapeutic exercise in patients with fibromyalgia.
Interventions
DEVICEReal tDCS
Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
DEVICESham tDCS
Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
DEVICETherapeutic exercise
The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
Sponsors
University of Castilla-La Mancha
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 65 years. * Fulfilled the 2010 American Colleague of Rheumatology criteria for fibromyalgia. * Normal pain intensity of 4 or more points on a visual analog scale. * Able to participated in a therapeutic exercise program. * Understanding of spoken and written Spanish.
Exclusion criteria
* Pregnancy or breastfeeding. * Metallic implants in the head. * Tumor, trauma or surgery in the brain. * Epilepsy or stroke. * History of substance abuse in the last 6 months. * Use of carbamazepine in the last 6 months. * Severe depression (Beck Depression Index II of 29 or more). * Diagnosed psychiatric pathology. * Rheumatic pathology not medically controlled. * Coexisting autoimmune pathology. * Chronic inflammatory disease (rheumatoid arthritis, erythematosus systemic lupus, inflammatory bowel disease).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in pain intensity from baseline to post-treatment | Baseline; immediately after intervention; 1-month after intervention | It will be measured with a visual analog scale (VAS) of 100 millimeters in length. The subject has to indicate the level of pain he feels, being 0 the absence of pain and 100 the maximum imaginable |
| Change in referred pain area after suprathreshold pressure stimulation from baseline to post-treatment | Baseline; immediately after intervention; 1-month after intervention | A pressure algometer (Force Ten™, Wagner Instruments, USA) will be used. It will be performed on the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) at a constant suprathreshold pressure (20% above the pressure pain threshold) for 60 seconds. After the stimulation, the subject should draw the induced pain area on a digital bodychart using the Navigate Pain application (Navigate Pain, Aalborg University, Denmark). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anxiety | Baseline; immediately after intervention; 1-month after intervention | The version adapted to Spanish from the State Scale (STAI-ES) of the State-Trait Anxiety Inventory (STAI) will be used. The scale ranges from 0 to 60. Higher values represent a worse result. |
| Depression | Baseline; immediately after intervention; 1-month after intervention | The adaptation to the Spanish of Beck Depression Inventory II will be used. The scale ranges from 0 to 63. Higher values represent a worse result. |
| Pain catastrophizing | Baseline; immediately after intervention; 1-month after intervention | The Spanish version of the Pain Catastrophizing Scale (PCS) will be used. The scale ranges from 0 to 52. Higher values represent a worse result. |
| Fibromyalgia Impact Quality-of-Life | Baseline; immediately after intervention; 1-month after intervention | It will be measured with the version adapted to the Spanish of the Fibromyalgia Impact Questionnaire (FIQ). The scale ranges from 0 to 100. Higher values represent a worse result. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Blinding | Immediately after intervention | Blinding of subjects and researchers will be assessed using the James Index. |
Countries
Spain
Outcome results
None listed